ArticlePLOS global public health2025
Concurrent use of low complexity automated NAATs for TB diagnosis and detection of resistance: A cost-effectiveness analysis.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Current TB diagnostics relying on respiratory samples are less effective in children (under 10 years), children living with HIV (CLHIV) and adult people living with HIV (PLHIV). Concurrent testing using low-complexity automated nucleic acid amplification tests (LC-aNAATs) on multiple sample types and Lateral Flow Lipoarabinomannan (LF-LAM) improves diagnostic performance, but concerns about cost-effectiveness remain. To inform WHO guideline development group (GDG) recommendation we developed stochastic decision analysis model to evaluate the cost-effectiveness of concurrent LC-aNAAT testing in these populations in Malawi and the Philippines. The analysis, conducted from a healthcare system perspective estimated incremental cost per disability-adjusted life year (DALY) averted using country-specific parameters from published literature and systematic review conducted for GDG. Concurrent testing was assessed using LC-aNAAT on respiratory and stool samples for children, LC-aNAAT on respiratory samples and LF-LAM for PLHIV, and a combination of both approaches for CLHIV. Concurrent testing in children compared to respiratory samples had incremental cost per DALY averted of $253 (95% uncertainty interval (UI): $123 to $2317) in Malawi and $156 (95% UI: $79 to $888) in the Philippines. For PLHIV, concurrent testing had an incremental cost per DALY averted of $42 (95% UI: $18 to $345) in Malawi and $28 (95% UI: $12 to $249) in the Philippines. In CLHIV, concurrent testing had an incremental cost per DALY averted of $43 (95% UI: $28 to $89) in Malawi and $29 (95% UI: $18 to $63) in the Philippines. Sensitivity analyses highlighted TB prevalence and respiratory sample availability as key influencers of cost-effectiveness. In scenarios with higher TB prevalence, cost-effectiveness improved, while an increase in the probability of producing respiratory sample resulted in worsening cost-effectiveness estimates. Concurrent use of LC-aNAATs on multiple sample types and in conjunction with LF-LAM emerged as highly cost-effective strategy for diagnosing TB among children, PLHIV, and CLHIV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.